feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Lancet Journal Raises Concerns Over Old Study

Lancet Journal Raises Concerns Over Old Study

7 Feb

•

Summary

  • A 2006 medical paper on codeine and infant death is under scrutiny.
  • New allegations of data falsification and ethical concerns emerged.
  • The study influenced global pain management and breastfeeding advice.

A 2006 medical case report published in The Lancet, which linked infant death to codeine passed through breast milk, is under renewed scrutiny. This paper has significantly impacted global pain management and breastfeeding advice for new mothers.

The Lancet added an 'expression of concern' on January 20, 2026, following allegations of falsified toxicological data, authorship issues, and ethical concerns. These allegations surfaced after a year-long investigation by The New Yorker and years of Canadian media coverage.

Critics argue the paper, authored by Gideon Koren, has been debunked for years. Outside researchers and two other medical journals have already retracted similar versions. The case study, focusing on an Ontario infant's 2005 death, purported that Tylenol 3, a common postpartum pain reliever containing codeine, was responsible.

Pharmacologist David Juurlink contends Koren misinterpreted toxicology results, suggesting the infant's high drug levels indicated direct administration rather than breast milk transmission. The Motherisk lab, founded by Koren, faced independent reviews deeming its testing methods unreliable, leading to its closure in 2019. Koren relinquished his medical license that same year.

Despite the criticisms and retractions of similar papers, the original case study has been cited over 600 times. Health Canada issued warnings in 2008, and drugmakers were urged to update labeling for codeine-based medications, affecting how postpartum pain medication is prescribed and potentially leading mothers to avoid breastfeeding.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The paper focused on an infant's death in 2005, purporting that codeine in the mother's breast milk caused the infant's poisoning.
New allegations of falsified toxicological data, authorship issues, and ethical concerns have been raised, prompting The Lancet to issue an 'expression of concern'.
The paper significantly influenced global approaches to pain management and breastfeeding guidance, leading to government warnings and changes in medication labeling.

Read more news on

Healthside-arrow
trending

Munich Air Disaster remembered

trending

US India trade agreement

trending

T20: Cricket's World Cup thrives

trending

India vs USA T20

trending

Chandrika Dixit's February 8 reveal

trending

Karnataka dominates Mumbai in Ranji

trending

T20 World Cup 2026 schedule

trending

Barcelona vs Mallorca live stream

trending

Jio Hotstar viewership rises

You may also like

Wegovy Pill Sees Explosive Demand Post-Launch

4 Feb • 21 reads

article image

Merck Stock Soars Amidst Drug Pricing Scrutiny

3 Feb • 32 reads

article image

Psychedelic Firm Sued for Trade Secret Theft

3 Feb • 6 reads

article image

FDA Clears Wegovy, Zepbound: No Suicidal Thoughts Link

13 Jan • 164 reads

article image

Viking CEO: Weight-Loss Deals More Intense Than Seen

13 Jan • 173 reads

article image